| Literature DB >> 27527701 |
Pirje Hütt1,2, Eleri Lapp1,2, Jelena Štšepetova1,2, Imbi Smidt1,2, Heleri Taelma1, Natalja Borovkova1,2, Helen Oopkaup1, Ave Ahelik1, Tiiu Rööp1,2, Dagmar Hoidmets1,2, Külli Samuel2, Andres Salumets2, Reet Mändar1,3.
Abstract
BACKGROUND: Vaginal lactobacilli offer protection against recurrent urinary infections, bacterial vaginosis, and vaginal candidiasis.Entities:
Keywords: Lactobacillus crispatus; Lactobacillus gasseri; Lactobacillus jensenii; probiotic; vaginal lactobacilli
Year: 2016 PMID: 27527701 PMCID: PMC4985617 DOI: 10.3402/mehd.v27.30484
Source DB: PubMed Journal: Microb Ecol Health Dis ISSN: 0891-060X
PCR primers and amplification conditions
| Primer pair | Target gene | Sequence 5′–3′ | Annealing temp (°C) | Amplicon size (bp) | Reference for primers |
|---|---|---|---|---|---|
| DI | RPP | GAYACNCCNGGNCAYRTNGAYTT | 50 | 1,083 | Clermont et al., 1997 ( |
| DI | GAYACNCCNGGNCAYRTNGAYTT | 55 | 1,513 | Clermont et al., 1997 ( | |
| TetS-F | ATCAAGATATTAAGGAC | 55 | 573 | Charpentier et al., 1993 ( | |
| TetO-F | AATGAAGATTCCGACAATTT | 55 | 781 | Sougakoff et al., 1987 ( | |
| TetK-F | TTATGGTGGTTGTAGCTAGAAA | 55 | 348 | Gevers et al., 2003 ( | |
| TetL-F | GTMGTTGCGCGCTATATTCC | 55 | 696 | Gevers et al., 2003 ( | |
| TetQ-F | AGAATCTGCTGTTTGCCAGTG | 56 | 169 | Ge et al., 2007 ( | |
| TetW-F | GAGAGCCTGCTATATGCCAGC | 64 | 168 | Kastner et al., 2006 ( | |
| ErmB-F | CATTTAACGACGAAACTGGC | 56 | 405 | Jensen et al., 1999 ( | |
| ermA-F | AAGCGGTAAACCCCTCTGA | 55 | 190 | Klare et al., 2007 ( | |
| Int | GGCATCCAAGCAGCAAG | 55 | – | Levesque et al., 1995 ( |
Fig. 1H2O2 production in lactobacilli strains of different study groups (135 Lactobacillus strains). −, negative; +, weak positive; ++, moderate positive; + + +, strong positive.
Antimicrobial activity of vaginal lactobacilli isolates against urogenital E. coli strains determined by a modified agar-spot method (inhibition zones in mm, expressed as mean±SD)
| Species | |||||
|---|---|---|---|---|---|
| 8.62±1.25* | 10.70±1.21 | 9.36±1.67** | 10.14±1.00*** | 10.42±1.28 | |
| 7.89±1.10 | 10.07±1.22 | 8.74±2.74 | 9.92±1.52 | 9.63±1.24 | |
| 6.47±2.23* | 9.67±1.75 | 6.90±3.18** | 8.58±2.66*** | 8.82±3.15 |
Three E. coli strains were previously isolated from women with bacterial vaginosis
reference strains: pyelonephritic strain of E. coli ATCC 700336 and cystitic strain of E. coli ATCC 700414. *p=0.0002; **p=0.003; ***p=0.006.
Fig. 2Anticandidal activity of vaginal lactobacilli (56 Lactobacillus strains). Significant differences in inhibition of Candida spp. between Lactobacillus spp.: *p<0.0001, *p<0.001.
Antibiotic susceptibility of the 31 Lactobacillus strains measured by E-test method
| AM | CL | CM | EM | GM | KM | MZ | NI | NX | SM | TC | TS | VA | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | 26 | 26 | 24 | 26 | 26 | 0 | 0 | 26 | 5 | 23 | 26 | 0 | 26 | |
| R | 0 | 0 | 2 | 0 | 0 | 26 | 26 | 0 | 21 | 3 | 0 | 26 | 0 | |
| S | 3 | 3 | 0 | 3 | 3 | 0 | 0 | 2 | 0 | 2 | 3 | 0 | 3 | |
| R | 0 | 0 | 3 | 0 | 0 | 3 | 3 | 1 | 3 | 1 | 0 | 3 | 0 | |
| S | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 0 | 1 | 2 | 0 | 2 | |
| R | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 2 | 1 | 0 | 2 | 0 |
AM, ampicillin; CL, chloramphenicol; CM, clindamycin; EM, erythromycin; GM, gentamycin; KM, kanamycin; MZ, metronidazole; NI, nitrofurantoin; NX, norfloxacin; SM, streptomycin; TC, tetracycline; TS, trimethoprim/sulfamethoxazole; VA, vancomycin; S, susceptible; R, resistant according to EFSA 2008.
Antimicrobial resistance genes in 31 selected Lactobacillus strains
| RPP | ||||||||
|---|---|---|---|---|---|---|---|---|
| Present | 14 | 0 | 0 | 0 | 6 | 0 | 6 | |
| Absent | 12 | 26 | 26 | 26 | 20 | 26 | 20 | |
| Present | 3 | 0 | 0 | 0 | 2 | 0 | 2 | |
| Absent | 0 | 3 | 3 | 3 | 1 | 3 | 1 | |
| Present | 1 | 1 | 0 | 0 | 0 | 0 | 1 | |
| Absent | 1 | 1 | 2 | 2 | 2 | 2 | 1 |
RPP, tet genes encoding ribosomal protection proteins.